About SMART™ Drugs

Xhale's Self-Monitoring And Reporting Therapeutics (SMART^TM) technology enables the creation of a breath-detectable version of any pharmaceutical drug. SMART^TM drugs release unique markers in the breath within minutes of ingestion, which can then be detected in the breath by using a small hand-held SMART monitor. Xhale's SMART system is the only existing technology which can definitively document patient adherence to a prescribed medication dosing regimen.

Market applications for SMART drugs include:

Disease Management: SMART versions of drugs targeted at patients where compliance is critical and challenging, such as antipsychotic drugs and therapeutics for Alzheimer's and other cognitive impairment diseases, would provide an advantage to patients, physicians and family caregivers.
Managed Care: SMART versions of drugs targeted at large patient subpopulations where improved patient adherence, tied to positive patient reward systems, can save money while providing better outcomes.
Pharmaceutical Clinical Trials: SMART versions of clinical trial medications will provide the only accurate and definitive means for tracking and recording patient adherence to the clinical trial dosing protocol.

While the first SMART drugs report via the breath on patient adherence, later generations will report on patient metabolism and therapeutic blood levels of the active pharmaceutical ingredient (API).

SMART has the potential to markedly improve the safety and efficacy of existing drugs while simultaneously providing market exclusivity from Xhale's patent protection on SMART technology.